anyone else notice triple agonist kicking in around week 65
anyone else notice triple agonist kicking in around week 65. Numbers below. Ask me the boring questions, they are the useful ones.
Kept a log specifically because there is so little published. It is one person and it is not data.
Where the evidence actually stands, since every thread here assumes a different answer.
Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.
Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.
Please do not ask me what dose you should be on. I genuinely do not know and neither does anyone else here.
best — the order this archive was captured in
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
Are you tracking heart rate at all?
[deleted]
Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.
Which phase 2 arm are you quoting, and at what week?
Removed the escalation schedule. There is no published protocol for members to follow and inventing one here is exactly what this board does not do.
the energy-expenditure story is mechanistically interesting and clinically unproven
Sent a vial to PeptideMeter out of curiosity. Result was 97.6% against a claimed 97.5%, which is the first independent number I had seen for this compound anywhere.
Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.
Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.
How fast was the escalation? That is usually the variable that explains the reports.
How fast was the escalation?
Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.
Are you comparing against phase 3 numbers for something else? They are not comparable.
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
The standing caveat, written out properly because it keeps getting compressed into a footnote.
Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.
What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.
Has anyone posted an independent test on this compound recently?
Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.
nothing here is available as a prescription product, so read every thread with that in mind
small trial, big effect, wide error bars